EDAP TMS S.A. Announces Preliminary H1 2026 Results; Expands into BPH & Endometriosis

What Happened

• On August 11, 2026, EDAP TMS S.A. (FOCL) announced preliminary unaudited estimated financial results for the six months ended June 30, 2026 via a press release (filed as Exhibit 99.1) and made an investor presentation available and filed as Exhibit 99.2.
• The investor presentation details strategic expansion of the company’s Focal One Robotic HIFU platform into two new indications: benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis. The filing reiterates these programs are investigational and not FDA‑cleared for these indications.

Key Details

• Date filed: August 11, 2026; results cover six months ended June 30, 2026 (preliminary, unaudited).
• BPH program: U.S. feasibility study has Institutional Review Board (IRB) approval; a multicenter feasibility study is underway outside the U.S. Company cites >100 million men worldwide with BPH and >13 million new cases annually (including >600,000 in the U.S.).
• Endometriosis program: Ongoing clinical development outside the U.S., including a randomized controlled pivotal study and a limited commercial launch in Europe under the CE mark. EDAP received FDA Breakthrough Device designation for endometriosis in 2024. Company cites ~38 million women affected worldwide and ~783,000 diagnosed annually (including ~225,000 in the U.S.).
• The filing includes standard forward‑looking statement caution: programs are investigational, regulatory clearance/approval is not guaranteed, and results may differ from expectations.

Why It Matters

• For investors, the 8‑K signals both near‑term financial disclosure (preliminary H1 2026 results) and strategic growth initiatives aimed at substantially larger patient populations (BPH and endometriosis).
• Clinical progress and a limited European commercial launch for endometriosis plus FDA Breakthrough Device designation could increase future revenue potential if trials and regulatory reviews succeed; however, these are investigational uses with no assurance of U.S. clearance.
• Monitor the company’s follow‑up filings for the actual H1 2026 financial numbers and clinical trial updates, since those will materially affect valuation and near‑term trading.